This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License
Lucinactant (trade name Surfaxin) is a liquid medication used to treat infant respiratory distress syndrome. It is a pulmonary surfactant for infants who lack enough natural surfactant in their lungs. Whereas earlier medicines of the class, such as beractant (Survanta & Beraksurf), calfactant (Infasurf), and poractant (Curosurf), are derived from animals, lucinactant is synthetic. It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on March 6, 2012.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:alternativeName |
|
| dbo:casNumber |
|
| dbo:fdaUniiCode |
|
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink |
|
| dbp:atcPrefix |
|
| dbp:atcSuffix |
|
| dbp:casNumber |
|
| dbp:component |
|
| dbp:tradename |
|
| dbp:type |
|
| dbp:unii |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| gold:hypernym | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of | |
| is foaf:primaryTopic of |